Charcot-Marie-Tooth Disease Type I – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Charcot-Marie-Tooth Disease Type I – Drugs In Development, 2024 report and make more profitable business decisions.
Charcot-Marie-Tooth disease, a group of hereditary sensory and motor neuropathies affecting peripheral nerves, leads to progressive damage connecting the brain and spinal cord to muscles and sensory cells. Manifesting in adolescence or adulthood, it causes sensation alteration, muscle wasting, and varying physical disabilities. Initial symptoms involve muscle atrophy in the feet, often accompanied by foot abnormalities, and difficulties in flexing or walking on the heels. As the disease advances, leg and hand weakness emerges, impacting daily activities. Sensory loss, decreased touch sensitivity, and occasional burning sensations follow. Subtypes like CMT1, characterized by myelin abnormalities, and CMT2, affecting nerve fibers, distinguish patterns of inheritance and manifestations. CMT1A is caused by having an extra copy (a duplication) of the PMP22 gene. Historical names, such as Roussy-Levy syndrome and Dejerine-Sottas syndrome, highlight additional features or early-onset severity in certain forms of the disease.
The Charcot-Marie-Tooth Disease Type I drugs in development market research report provide comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease Type I, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Charcot-Marie-Tooth Disease Type I and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Charcot-Marie-Tooth Disease Type I | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 25 molecules, with 22 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Charcot-Marie-Tooth Disease Type I therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Charcot-Marie-Tooth Disease Type I pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Charcot-Marie-Tooth Disease Type I treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Addex Therapeutics LtdAffectis Pharmaceuticals AG
Armatus Bio LLC
Augustine Therapeutics
Cedars-Sinai Medical Center
Cellatoz Therapeutics Inc
Cyprus Institute of Neurology and Genetics
Encell Co Ltd
GeneNet Co Ltd
Helixmith Co Ltd
Imnewrun Bioscience Co Ltd
InFlectis BioScience SAS
Ionis Pharmaceuticals Inc
Lead Discovery Center GmbH
Nervosave Therapeutics
NMD Pharma AS
Novartis AG
Oryzon Genomics SA
Pharnext SA
Samsara Therapeutics Inc
Sanofi
Shape Therapeutics Inc
ToolGen Inc
UGISense AG
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Charcot-Marie-Tooth Disease Type I reports